Part-Time

Registered Nurse/Registered Psychiatric Nurse – Addictions Assessment

Updated on 8/20/2026

Deadline 3/30/27
Fraser Health

Fraser Health

10,001+ employees

Public health authority operating hospitals

Compensation Overview

CA$41.42 - CA$59.52/hr

Harrison Hot Springs, BC, Canada + 2 more

More locations: Agassiz, BC, Canada | Hope, BC, Canada

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
CPR
Electronic Health Records (EHR)
Risk Management
Patient Education

Get referred to Fraser Health

See people who can refer or advise you

Requirements
  • Graduation from an approved nursing program with current practicing registration as a Registered Nurse and/or Registered Psychiatric Nurse with the British Columbia College of Nurses and Midwives.
  • Completion of approved addictions or substance-use training or a substance-use certificate program, plus one year of recent related experience working in an addictions environment with individuals with substance-use disorders, or an equivalent combination of education, training, and experience.
  • Successful completion of the St. John Ambulance Safety Oriented First Aid Certificate and a current Cardiopulmonary Resuscitation Certificate, Level C.
  • Ability to complete initial and ongoing mental-health and substance-use patient assessments and provide nursing care through appropriate or prescribed technical, therapeutic, and safety interventions, including crisis intervention.
  • Knowledge of mental illness and substance-use treatment.
  • Knowledge of psychopharmacology, including indications and side effects.
  • Knowledge of counselling and group-facilitation skills.
  • Knowledge of legislation and government policies and procedures related to mental-health and substance-use practices.
  • Ability to communicate effectively verbally and in writing with patients, families or caregivers, the public, medical staff, and members of the interprofessional care team.
  • Ability to promote person-centered care with empathy, cultural sensitivity, and responsiveness to diverse patient and family preferences, including advocacy for special populations.
  • Ability to educate patients and families or caregivers about topics essential to their health care and well-being.
  • Ability to organize and prioritize work.
  • Ability to collaborate with and promote cooperation among members of the interprofessional care team.
  • Ability to use factual information and basic principles and procedures to support nursing decisions and actions with relevant research-based or evidence-informed practice.
  • Ability to operate related equipment, including relevant computer applications.
  • Physical ability to perform the duties of the position.
Responsibilities
  • Plan and provide direct nursing care in compliance with standards of practice by reviewing patient and family histories, charts, and other written information; observing patients; conducting physical and psychosocial assessments; interviewing patients and natural supports; completing questionnaires; and consulting with colleagues and other health-team members.
  • Assess patient needs and plan, implement, evaluate, and prioritize nursing care and interventions to develop patient-specific care plans using clinical judgment and evidence-based practice.
  • Make referrals to identified resources as required.
  • Provide general and crisis counselling to patients presenting to the Emergency Department, including short-term follow-up under approved treatment plans authorized by an emergency-room or consulting physician.
  • Share information collegially with Emergency Nurses regarding physician orders, including initiating unit standing orders, administering medications, carrying out treatments, and monitoring and documenting effects.
  • Process physician orders as assigned.
  • Manage emergencies such as drug overdose, heart attack, assaultive behaviour, and seizures by providing direct nursing interventions and responding according to established policies and procedures, including initiating cardiopulmonary resuscitation or alerting ambulance or police services.
  • Establish and maintain effective relationships with Emergency, Addictions Medicine, and other interdisciplinary team members to facilitate communication and care decisions, resolve patient and family issues, identify service gaps, and improve services for individuals with substance-use issues.
  • Participate in patient-care conferences, rounds, and staff meetings and contribute relevant information.
  • Assess patient and family learning needs and determine required instruction.
  • Provide and explain information, demonstrate procedures and equipment use, check learners' use of procedures and equipment, and plan, coordinate, and deliver educational sessions.
  • Facilitate education sessions for patients, family members, service providers, and community agencies on withdrawal management, relapse prevention, stress management, illness prevention, health maintenance, health promotion, self-care, problem-solving, and coping skills.
  • Evaluate the effectiveness of teaching methods and learning outcomes.
  • Act as a clinical resource and support person for patients and families, nurses, and health-care professionals by explaining the rationale for nursing decisions and providing clinical consultation to Mental Health Care Workers.
  • Participate in the training, orientation, and continuing education of nursing staff and students through mentoring, preceptoring, and role-modeling.
  • Maintain complete and current clinical records, including electronic health-care information in systems such as Meditech, nursing observations, communications, progress notes, interventions, teaching, care evaluations, patient outcomes, and discharge summaries.
  • Advocate for patients' rights to dignity, respect, privacy, confidentiality, autonomy, and access to information.
  • Participate in quality-improvement and risk-management activities, including reporting high-risk situations, evaluating changes in nursing practice, generating recommendations, conducting safety audits, and identifying corrective actions.
  • Maintain a safe environment for patients, visitors, and employees by following safety and emergency procedures and reporting risks and anomalies to the Patient Care Coordinator.
  • Participate in program development and clinical-service delivery, including internal conferences and the development, implementation, and evaluation of patient-program activities and treatment approaches.
  • Identify learning needs and goals, review them with the Patient Care Coordinator, and undertake activities to meet them.
  • Participate in developing, implementing, and evaluating policies and procedures; interpret them for patients, agencies, and the public; and refer unusual inquiries to the Patient Care Coordinator.

Fraser Health is a health authority in British Columbia that provides a wide range of medical services to about 1.8 million people. It operates 12 hospitals, including major trauma centres, plus an outpatient care and surgery centre, and offers residential care, home health, public health, and mental health services. The organization employs over 40,000 staff, medical professionals, and volunteers who run clinics, care centres, and community programs. Its goal is to deliver accessible, high-quality care across the network while creating good workplaces for its employees and volunteers.

Company Size

10,001+

Company Stage

Grant

Total Funding

$20K

Headquarters

Surrey, Canada

Founded

2001

Get referred to Fraser Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fraser Health won $1.3 million March 2026 to expand Indigenous elder home care.
  • Royal Columbian Hospital activated March 24, 2026, adding one more clinical-trial site.
  • Surrey’s new UPCC opened January 28, 2026, targeting 64,000 annual patient visits.

What critics are saying

  • Mission Memorial’s ED shut down May 25, 2026, exposing persistent physician staffing gaps.
  • Peace Arch maternity closed for the sixth time in March 2026, signaling brittle coverage.
  • Cloverdale hospital costs reached $2.88 billion, and completion slipped to August 2029.

What makes Fraser Health unique

  • Fraser Health runs 12 hospitals across 20 communities, anchoring Lower Mainland acute care.
  • Its Indigenous-led home-care programs integrate Stó:lō, FNHA, and Métis partners.
  • Fraser Health is deploying AI scheduling with Deloitte and Scale AI across hospitals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
StockTitan
Mar 24th, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial.

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Arch Biopartners (OTCQB: ACHFF) announced a Clinical Trial Agreement with Fraser Health Authority to prepare Royal Columbian Hospital for recruitment in its Phase II trial of LSALT peptide for prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Royal Columbian Hospital is now the ninth global site activated and the fourth Canadian recruiting site, after Toronto General Hospital, St. Michael's Hospital, and University of Calgary. Positive. * Royal Columbian Hospital received final Research Ethics Board and operational approvals * Royal Columbian Hospital became the 9th global site activated in the Phase II CS-AKI trial * 4 Canadian sites are actively recruiting patients (Toronto General, St. Michael's, Calgary, RCH) Negative. 03/24/2026 - 09:13 AM TORONTO, March 24, 2026 (GLOBE NEWSWIRE) - Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA") with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada. Toronto General Hospital, part of University Health Network, St. Michael's Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: * LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. * Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. * CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide[1]. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. For more details about the Company's science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news. The Company has 66,933,289 common shares outstanding. | Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | / | | / | / | Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company's future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in the Company's most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company's most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedarplus.ca. References: * Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext The scientific and medical content of this release has been reviewed and approved by the Company's Chief Science Officer. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Faq. What does the Clinical Trial Agreement with Fraser Health mean for Arch Biopartners (ACHFF)? It enables Royal Columbian Hospital to prepare for patient recruitment in the Phase II CS-AKI trial. According to the company, RCH now has final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health, supporting site activation. How many sites are active in Arch Biopartners' (ACHFF) Phase II LSALT CS-AKI trial after Royal Columbian Hospital activation? Royal Columbian Hospital is the ninth site activated globally in the study. According to the company, RCH is also the fourth site in Canada to reach activation and prepare for recruitment. Which Canadian hospitals are currently recruiting for Arch Biopartners' (ACHFF) Phase II CS-AKI trial? Toronto General Hospital, St. Michael's Hospital, University of Calgary, and now Royal Columbian Hospital are recruiting. According to the company, those four Canadian centres are actively enrolling new patients into the trial. What approvals did Royal Columbian Hospital receive to start recruitment for the ACHFF Phase II trial? RCH received final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health. According to the company, these approvals complete site readiness for recruitment and study start-up activities. Will Arch Biopartners (ACHFF) add more sites in Canada and the US for the Phase II CS-AKI trial? The company is progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. According to the company, those discussions aim to expand site activation beyond the current nine global sites.

Black Press Media
Mar 14th, 2026
$1.3M funding will help more Indigenous elders in Chilliwack with at-home care

$1.3M funding will help more Indigenous elders in Chilliwack with at-home care. Published 8:45 am Saturday, March 14, 2026 An at-home program that offers care to Indigenous elders in the Fraser Valley will be expanding, with the main focus on Chilliwack, thanks to $1.3 million in new funding. The Indigenous Caregiver Support Model (ICSM) is a home-based program that supports elders with "complex needs to age safely at home and in their community," according to a Fraser Health press release. It is one of five programs in B.C. benefitting from a total of $6.3 million in funding from Health Research BC over the next three years. The funding will advance research to help B.C. seniors age comfortably in their own home. The ICSM program was launched in 2023 as a pilot project and has supported 33 elders and their caregivers in the Eastern Fraser Valley, including Chilliwack. Its aim is to reduce caregiver strain and improve elder wellbeing by providing culturally safe, coordinated in-home support, training, and financial assistance for Indigenous families caring for elders. It is co-designed by Fraser Health Indigenous Health, Stó:lō Service Agency, First Nations Health Authority, and Métis Nation British Columbia. "This model is an example of what is possible when care is built on relationships, trust and community," said Amanda LaBoucane, interim vice president, Indigenous Health and Cultural Safety. "Many elders and caregivers in the Chilliwack area have experienced firsthand the impacts of residential schools and the child welfare system. By strengthening caregiver capacity and confidence while bridging into integrated clinical care teams run by and for Indigenous people, we see improved health and wellness and stronger relationships within and between communities." The program is currently operating in the Fraser Valley, including Chilliwack, but the expansion will focus on urban Chilliwack as that is an identified need, said Carrie Stefanson with Fraser Health. Caregivers receive skills training and an honorarium to help reduce the economic strain of caregiving, while elders receive regular home visits from Indigenous-led clinical teams who provide culturally safe, relationship-based care, rooted in trust, kindness and respect, according to a Fraser Health.

Fraser Health
Sep 12th, 2024
Leveraging artificial intelligence to assist with scheduling

Fraser Health has partnered with Deloitte Canada to develop and launch scheduling tools that leverage artificial intelligence (AI) and machine-learning solutions to accurately forecast the waves in demand Fraserhealth see in the health system.

Government of British Columbia
Aug 22nd, 2024
Permanent supportive, complex-care homes open in Fraser Valley

For people not already connected to services, Fraser Health will work in partnership with Coast Mental Health to provide on-site clinical supports, including services from a psychiatric nurse, community nurse, licensed practical nurse, social worker and traditional wellness practitioners.

Daily Hive
Sep 12th, 2023
Construction begins on Surrey's new $2.9 billion Cloverdale hospital

Through a procurement process, Fraser Health has selected Ellis-Don Design Build to design and build the new facility through a design-build agreement.